Clofarabine

It is a nucleotide analogue developed by Bioenvision and manufactured by Genzyme. On ☆December 29, 2004, it was approved by FDA for the treatment of refr✔actory or relapsed acute lymphoblastic leukemia (ALL) in children.

key word:

manufactured treatment

Category:

Product Description

Integrity, innovation, cooperation, sharing, win-win

The company integrates multiple resources and strives to build a large health industry βfinance platform company integrating pharmaceutical, intelligent medical, bio pharmaceutical R&♣;D, industrial production and sales.

The chemical reactions involved in the existing products include Foucault reaction, nitrationε reaction, sulfonation reaction, hydrogenation reaction, fluorination reaction, chlorination ™reaction, bromination reaction, diazotization reaction, format reaction, etc.

It is a nucleotide analogue developed by Bioenvision and manufactured by Genzyme. On December 29,≈ 2004, it was approved by FDA for the treatment of refractory or relapαsed acute lymphoblastic leukemia (ALL) in children.

Clofarabine is the first new drug approved for pediatric ALL in the last 10 years. It can b•ring continuous remission to some children and create conditions for some children ₩to receive bone marrow transplantation. It is a new effective and we‌ll-tolerated treatment option for children with high resistance leukemia. Clofarabine has also show'n promise in children with relapsed or refractory acute myeloid leukemia.

Clofarabine HAS POTENTIAL BROAD SPECTRUM ANTITUMOR PROPERTIES: With more thφan 20 clinical indications in the United States, CLOfarabine is aδ broad spectrum anticancer drug with great potential.

Now in clinical indications are: breast, lung, colorectal, prostate, k♦idney cancer, cervical cancer, pancreatic cancer, skin cancer, bladder c®ancer, non-small cell lung cancer, oral cancer, nasopharyngeal carcinoma, laryngeal cancer, maxillaεry sinus carcinoma, esophageal cancer, uterus tumor, melanoma, leiomyosa×rcoma of the bulk of the phase I clinical study has been done. Acute myelogenous leukemia∞, chronic lymphoma, and non-Hodgkin's lymphoma are in phase II clinical studies, and inh₽ibition of graft rejection is in phase I clinical studies. So while it is used to treat acuλte leukemia, its potential indications include many solid tumors as well as some immu★ne diseases.

Related products

Sitagliptin Phosphate Monohydrate

Sitagliptin phosphate is a dipeptidyl peptidase-4 (DPP4) inhibitor developed by Merck. In​ October 2006, Sitagliptin phosphate Januvia was approved by FDA as the first DPP4ε inhibitor for the treatment of type ⅱ diabetes mellitus. The characteristics ✘of this drug are that it can stimulate insulin secretion while reducing εhunger without causing weight gain. Hypoglycemia and edema will not occur, and it <is suitable for diabetic patients with poor blood glucose control and fr£equent hypoglycemia.

Sumatriptan Succinate

Medication for migraine

Vildagliptin

Chenglian Pharmaceutical is an innovative high-tech pharmaceutical enterprise tha≈t is market-oriented and realizes industrial development through R&D ±innovation and technology transformation.

Ketoprofen

The non-steroidal anti-inflammatory drug ketoprofen is one of the mos₹t important products for the treatment of arthritis. It≥ is well tolerated and has a low incidence of side effects

Pranlukast

Pranlukast, developed by Ono, is one of the three major leuk£otriene receptor antagonists. In clinical applicati∑on, it has good therapeutic effect on atopic asthma and other ↕types of bronchial asthma, and the market prospect is huge. In the major category of asthma drugs,↕ leukotriene receptor antagonists have the fastest growing market share.

Avanafil

Chenglian Pharmaceutical is an innovative high-tech pharmaceutical enterprise that is market- oriented and realizes industrial development through R&D innovation and tech&nology transformation.

Donepezil HCL

Treatment of mild to moderate Alzheimer's syndrome. It is the secon d drug approved by FDA for Alzheimer's disease in the United Sta₩tes. Its treatment reaches the target dose and has low toxic and side effects. It has been wide"ly recognized by our medical community, and good tole₽rance is its biggest advantage. In October 1999, Donepezil was launched in Ch¶ina under the trade name "Aricept", which is the main chemical drug against Alzheime‌r's disease. At present, CFDA has approved a number of domestic enterprises to produce donepe​zil preparations, the main dosage forms are tablets, capsules, dispersive tablets,> oral disintegrating tablets.

Almotriptan

Migraine medication for adolescents

Apixaban

English name Apixaban Trade name ELIQUIS, tablet: Apixaban (Eliquis, Bristol-Myers Squibb/Pfizer), ✔a direct oral factor Xa inhibitor, was approved for use✘ in the 27 EU member states. The world's first drug  approved to prevent venous thromboembolism (VTE) in adult patients undergoing elective hip or kne₩e replacement. From June 2019 to June 2020, the annual sales of apixaban products¶ overseas reached about $15.4 billion, with a year-on-year growth of nearly 32%, and the API c♠onsumption reached about 23,960 kg, with a year-on-year growth of about 28%. Compare♣d with its main competitor, Rivaroxaban, the drug's ☆annual overseas sales are about $4.5 billion higher.

Lenvatinib

Chenglian Pharmaceutical is an innovative high-tech pharmaceutical enterprise™ that is market-oriented and realizes industrial development thr→ough R&D innovation and technology transformation.'

Clofarabine

It is a nucleotide analogue developed by Bioenvision and manufactured by Genzyme. Oπn December 29, 2004, it was approved by FDA for the treatment of refractory∏ or relapsed acute lymphoblastic leukemia (ALL) in children.

Upadacitinib(Scientific research)

Chenglian Pharmaceutical is an innovative high-tech pharmaceutical enterpris±e that is market-oriented and realizes industrial development through R&D in±novation and technology transformation.

Product Consulting

Our staff will contact you within 24 hours (working days). If you need¥ other services, E-mail: 2880705932@qq.com